# OPKO Health, Inc. clinical trials: 49 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 49 trials with OPKO Health, Inc. as lead sponsor, 2 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by OPKO Health, Inc.: 49 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/opko-health-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 49
- Recruiting or not yet: 2
- Read on: November 19, 2026

## Trials

The 25 newest of 49, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| April 6, 2026 | NCT07512427 | Phase 1/2 Study of OPK-88006 in Healthy and Presumed MASH Participants | OPKO Health, Inc. | Phase 1/2 | Recruiting | MASH | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07512427) |
| March 27, 2026 | NCT07494045 | Pharmacokinetics, Pharmacodynamics, Safety and Tolerability Evaluation of CTAP101 Extended-release Capsules in Pediatric Participants | OPKO Health, Inc. | Phase 2 | Recruiting | CKD Stage 3, CKD Stage 4, Secondary Hyperparathyroidism, VDI | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07494045) |
| September 16, 2022 | NCT05543928 | Phase 3 Safety and Efficacy Study of CTAP101 Extended-release Capsules in Children With Secondary Hyperparathyroidism | OPKO Health, Inc. | Phase 3 | Terminated | Chronic Kidney Disease stage3, Chronic Kidney Disease stage4, Vitamin d Deficiency, Secondary Hyperparathyroidism | 2 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05543928) |
| September 16, 2020 | NCT04551911 | Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19 | OPKO Health, Inc. | Phase 2 | Completed | COVID-19, Coronavirus, SARS-CoV2 Infection | 171 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04551911) |
| October 17, 2019 | NCT04130776 | 4Kscore Using Serum Stored Uncentrifuged | OPKO Health, Inc. | Observational | Completed | Prostate Cancer | 64 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04130776) |
| August 21, 2019 | NCT04063644 | Quality of Life and Visual Acuity of Visglyc Eye Drops on Dry Eye Patients | OPKO Health, Inc. | Not applicable | Completed | Dry Eye Syndromes, Cataract | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04063644) |
| March 14, 2019 | NCT03874013 | Safety and Efficacy Study of MOD-4023 to Treat Children With Growth Hormone Deficiency | OPKO Health, Inc. | Phase 3 | Completed | Growth Hormone Deficiency | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03874013) |
| January 22, 2019 | NCT03810664 | A Clinical Study Investigating the Comparability of Somatrogon in Two Different Drug Product Presentations | OPKO Health, Inc. | Phase 1 | Completed | Healthy Male Volunteers | 49 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03810664) |
| December 3, 2018 | NCT03762408 | Efficacy and Safety of a Intra-articular Injection, ENKO1, in Patients With Symptomatic Knee Osteoarthritis. | OPKO Health, Inc. | Not applicable | Completed | Osteoarthritis, Knee | 175 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03762408) |
| September 7, 2018 | NCT03660800 | Pharmacokinetics and Safety Study of CTAP101 Capsules in Japanese and Non-Japanese Healthy Subjects and Non-Japanese Healthy Subjects | OPKO Health, Inc. | Phase 1 | Completed | Vitamin D Insufficiency, Secondary Hyperparathyroidism | 67 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03660800) |
| July 26, 2018 | NCT03602261 | Safety, Efficacy, PK and PD of CTAP101 (Calcifediol) ER Capsules for SHPT in HD Patients VDI | OPKO Health, Inc. | Phase 2 | Terminated | Secondary Hyperparathyroidism Due to Renal Causes, Chronic Kidney Diseases, Vitamin D Deficiency, Stage 5 Chronic... | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03602261) |
| July 17, 2018 | NCT03588884 | Repeated-dose Safety, Efficacy, Pharmacokinetic and Pharmacodynamic of CTAP101, Immediate-release Calcifediol, High-dose Cholecalciferol... | OPKO Health, Inc. | Phase 4 | Completed | Secondary Hyperparathyroidism Due to Renal Causes, Vitamin D Insufficiency, CKD Stage 3, CKD Stage 4 | 69 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03588884) |
| January 23, 2018 | NCT03406377 | Effects and Safety of OPK-88003 Dose Escalation in Type 2 Diabetes Subjects | OPKO Health, Inc. | Phase 2 | Completed | Type 2 Diabetes Mellitus | 113 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03406377) |
| November 28, 2017 | NCT03355651 | Efficacy and Tolerability of a Nutritional Supplement, Plactive Progen, in ACL Reconstruction | OPKO Health, Inc. | Not applicable | Completed | ACL Reconstruction | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03355651) |
| September 29, 2017 | NCT03297398 | Effects and Safety of OPK-88004 Doses in Men With Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) | OPKO Health, Inc. | Phase 2 | Terminated | Benign Prostatic Hyperplasia | 114 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03297398) |
| November 18, 2016 | NCT02968004 | Safety and Efficacy Phase 3 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children | OPKO Health, Inc. | Phase 3 | Completed | Pediatric Growth Hormone Deficiency | 224 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02968004) |
| September 29, 2016 | NCT02919800 | A Single-dose, Dose-escalation Study of a Long-acting MOD-5014 in Healthy Adult Male | OPKO Health, Inc. | Phase 1 | Completed | Hemophilia A or B With Inhibitors | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02919800) |
| February 26, 2016 | NCT02692781 | A Single-dose, Dose-escalation Study of a Long-acting MOD-6031 in Healthy Overweight or Obese Subjects | OPKO Health, Inc. | Phase 1 | Completed | Obesity | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02692781) |
| July 16, 2015 | NCT02500316 | Long Term Follow up Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children | OPKO Health, Inc. | Phase 2 | Completed | Growth Hormone Deficiency (GHD) | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02500316) |
| April 16, 2015 | NCT02418793 | A Study of a Long-Acting r-Factor 7a (Factor VIIa) in Adult Men With Hemophilia A or B | OPKO Health, Inc. | Phase 1 | Completed | Hemophilia A, Hemophilia B | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02418793) |
| April 16, 2015 | NCT02418767 | Pharmacokinetics and Pharmacodynamics of Long Acting Human Growth Hormone (hGH) Product (MOD-4023) in Healthy Caucasian and Japanese... | OPKO Health, Inc. | Phase 1 | Completed | Growth Hormone Deficiency | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02418767) |
| November 4, 2014 | NCT02282813 | Extension Study of CTAP101-CL-3001 or CTAP101-CL-3002 | OPKO Health, Inc. | Phase 3 | Completed | Chronic Kidney Disease, Hyperparathyroidism, Secondary, Vitamin D Deficiency | 298 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02282813) |
| October 24, 2014 | NCT02274623 | Effect of CTAP101 Capsules on Ca/iPTH in Advanced Breast/Prostate Cancer Patients Treated With Denosumab/Zoledronic Acid | OPKO Health, Inc. | Phase 1 | Completed | Breast Cancer, Prostate Cancer, Bone Neoplasms, Hypocalcemia, Hyperparathyroidism, Secondary | 33 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02274623) |
| July 11, 2014 | NCT02188303 | A Study of LY2944876 in Healthy Japanese and Non-Japanese Participants | OPKO Health, Inc. | Phase 1 | Terminated | Healthy Volunteers | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02188303) |
| April 22, 2014 | NCT02119819 | A Study to Compare a New Drug for Type 2 Diabetes to Placebo and to a Treatment Already Available for Type 2 Diabetes | OPKO Health, Inc. | Phase 2 | Completed | Diabetes Mellitus, Type 2 | 420 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02119819) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 14 |
| Phase 1/2 | 1 |
| Phase 2 | 20 |
| Phase 2/3 | 1 |
| Phase 3 | 7 |
| Phase 4 | 1 |
| Not applicable | 4 |
| Observational | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 37 |
| Terminated | 8 |
| Withdrawn | 2 |
| Recruiting | 2 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Hyperparathyroidism, Secondary | 7 |
| Dwarfism, Pituitary | 5 |
| Alzheimer Disease | 4 |
| Macular Degeneration | 4 |
| Diabetes Mellitus, Type 2 | 4 |
| Renal Insufficiency, Chronic | 4 |
| Vitamin D Deficiency | 3 |
| Psychomotor Agitation | 2 |
| Aggression | 2 |
| Parathyroid Diseases | 2 |
| Renal Insufficiency | 2 |
| Kidney Failure, Chronic | 2 |
| Hyperparathyroidism | 2 |
| Kidney Diseases | 2 |
| Prostatic Neoplasms | 2 |
| Hemophilia A | 2 |
| Edema | 1 |
| Retinal Diseases | 1 |
| Prostatic Hyperplasia | 1 |
| Hepatitis C, Chronic | 1 |
| Hepatitis, Viral, Human | 1 |
| Hepatitis C | 1 |
| Glaucoma | 1 |
| Osteoarthritis, Knee | 1 |
| Osteoarthritis | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Automotive companies in the United States](https://specstream.ai/data/businesses/automotive-companies/united-states)
- [Plastic manufacturers in the United States](https://specstream.ai/data/businesses/plastic-manufacturers/united-states)
- [Financial services firms in the United States](https://specstream.ai/data/businesses/financial-services-firms/united-states)
- [Arabian restaurants in the United States](https://specstream.ai/data/businesses/arabian-restaurants/united-states)
- [Pediatric orthopedic surgery practices in the United States](https://specstream.ai/data/businesses/pediatric-orthopedic-surgery-practices/united-states)
- [Eye care clinics in the United States](https://specstream.ai/data/businesses/eye-care-clinics/united-states)
